Oxytocin Effects on Bone in Children With Autism Spectrum Disorder
NCT05754073
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin on bone health in children with autism spectrum disorder, ages 6-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (30 IU, 2 times daily) for 12 months in the double-blind phase, followed by a 6-month open label phase during which all study subjects will receive intranasal oxytocin (30 IU, 2 times daily).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Autism Spectrum Disorder
- Bone Health
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 6 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Elizabeth Austen Lawson
- Last updated on ClinicalTrials.gov
- March 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Virginia · 1
- University of Virginia Medical Center · Charlottesville, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.